**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 52-year-old man developed COVID-19 pneumonia during treatment with mycophenolate-mofetil, prednisone and tacrolimus \[*not all dosages and routes stated; duration of treatments to reactions onsets not stated*\].

The man underwent kidney transplantation for his chronic glomerulonephritis before 12 years. He also underwent haemodialysis for 4 years before transplantation. He then received triple maintenance immuno-suppressive therapy with oral tacrolimus, prednisone and mycophenolate mofetil. On 20 January 2020, he went to Wuhan to visit his relative. After his visit, he showed initial symptoms of dyspnoea, tightness and pain in the chest, nausea, loss of appetite, intermittent abdominal pain, occasional dry coughs, and fatigue on 28 January 2020. On 30 January 2020, he developed a headache and fever. He did not visit a doctor and remained at his relative\'s place till 02 Feb 2020. Because of intensification of his symptoms, he visited the clinic on 02 Feb 2020 and he had a body temperature of 38.9°C. His laboratory tests indicated lowered lymphocyte count and lymphocyte percentage, higher monocyte, C-reactive protein, and neutrophil counts. His chest CT indicated multiple patchy ground-glass density shadows in the lungs suggesting the possibilty of COVID-19 pneumonia.

Immunosuppressive agents were discontinued. The man was treated with oral umifenovir tablets 0.2g thrice a day and moxifloxacin tablets 0.4g daily. On day 8 of illness, polymerase chain reaction (PCR) assay confirmed COVID-19. His symptoms continued and he was admitted to an isolation ward in the hospital. He had lost 10kg of body weight within one week due to poor eating. On admission to the isolation ward, his physical examination revealed a body temperature of 37.7°C. On second day of admission, his body temperature was 38°C. A blood gas analysis revealed that the partial pressure of oxygen was 77.4 mmHg, the partial pressure of carbon dioxide was 35 mmHg, and pH level was 7.368. Therefore, oxygen was administered at 2 L/min via a nasal catheter. He received IV methylprednisolone 40mg daily and IV immune-globulin \[immunoglobulin\] 5g on the first day and 10g daily for next 11 days. He also received biapenem 0.3g every 12 hours through IV drip, pantaprazole and interferon-α 5 million units daily through inhalation. On day 5 of admission, his body temperature returned to normal, chest tightness and nausea were relieved. Treatment with oral tacrolimus was resumed at half its original dosage after 5 days of complete discontinuation. On day 6, his CRP started decreasing; however, a chest CT revealed appearance of new lesions. His serum alanine aminotransferase (ALT) levels also found to be increased. He then received glycyrrhizic acid diamine to protect liver function. On day 9 of admission, his weakness and dry cough improved significantly. A repeat throat swab sample was negative for COVID-19. Subsequently, his CRP levels decreased and the lymphocyte count began to rise. On day 11 of admission, he felt well, and COVID-19 nucleic acid again tested negative. A third chest CT revealed complete resolution of the lung lesions. Supplemental oxygen was withdrawn and his oxygen saturation values were maintained above 96%. Treatment with oral tacrolimus and mycophenolate-mofetil was started at pre-illness dosage levels. On day 13 of hospitalisation and illness day 21, he was discharged from hospital. Since then, he was in good health.
